Informations générales (source: ClinicalTrials.gov)

NCT03609112 En recrutement IDF
Neurocognitive Risks in Children With Solid Tumors
Observational [Patient Registry]
  • Tumeurs
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
octobre 2014
septembre 2025
13 septembre 2025
The survival rate of children with cancer has improved significantly in recent years thanks to the progress of different therapies. The neurocognitive sequelae related to treatments and illness are more or less well known. Four factors seem to be associated with neurocognitive sequelae: treatment, the tumor itself, environmental factors like the socio-economic status of parents and biological factors. Main purpose of the study is to establish a score to assess the risk of neurocognitive sequelae in these children based on these factors (treatment, tumor, and environmental factors)
 Voir le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CLCC INSTITUT GUSTAVE ROUSSY Christelle DUFOUR En recrutement IDF 16/04/2024 09:21:16  Contacter

Critères

Tous
Inclusion Criteria:

- Patient aged 6 to 16 years and 11 months during the study period

- Type of pathology: solid tumor

- Place of treatment and follow-up: Gustave Roussy

- Minimum time from the end of the initial treatment:

- For patients who have not received treatment with methotrexate: 6 months

- For patients being treated with methotrexate: none

- Obtaining the non-opposition of parents / legal representatives

- Affiliation to a social security scheme.


- Patients with other pathologies associated with mental retardation (autism, genetic
syndrome ...)

- Patients lost to follow-up

- Deceased patients

- Patients treated for a pathology whose prognosis is involved in the very short term
(infiltrating glioma of the brainstem, recurrence of the pathology during treatment)

- Non-French speaking patients